Investigating kava's potential to reduce lung cancer risk in smokers
Quantifying NNK metabolites to facilitate Kava lung cancer prevention clinical translation
This study is looking at whether drinking kava, a traditional beverage from the South Pacific, can help lower the risk of lung cancer for smokers by potentially blocking harmful substances in tobacco.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10683294 on NIH RePORTER |
What this research studies
This research explores the potential of kava, a beverage from the South Pacific, to reduce the risk of lung cancer among smokers. It builds on previous findings that suggest kava may block the effects of tobacco-specific carcinogens, particularly NNK, which is linked to lung cancer. The study will utilize both human epidemiological data and pre-clinical animal studies to assess how kava can enhance the detoxification of carcinogens and reduce DNA damage. By focusing on the mechanisms behind kava's protective effects, the research aims to improve its clinical application for lung cancer prevention.
Who could benefit from this research
Good fit: Ideal candidates for this research are smokers who are at risk of lung cancer and are interested in alternative methods for risk reduction.
Not a fit: Patients who do not smoke or have never smoked may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel approach to lung cancer prevention for smokers through the use of kava.
How similar studies have performed: Previous studies have shown promising results regarding kava's potential in reducing cancer risk, suggesting that this approach may be viable.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Xing, Chengguo — University of Florida
- Study coordinator: Xing, Chengguo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.